Patient-reported outcomes (PROs) measure aspects of a patient's health status that comes directly from the patient, including health-related quality of life (HRQoL). HRQoL instruments provide a means of assessing treatment benefit and can be important tools in clinical research and practice.59-61 HRQoL is becoming an increasingly important assessment tool in multiple myeloma, given the improved survival outcomes from recent treatment advances. There are multiple well-validated instruments available which can be used in clinical trials to facilitate comparisons between treatments.60,62
CIPN, chemotherapy-induced peripheral neuropathy; EORTC, European Organisation for Research and Treatment of Cancer; FACT, Functional Assessment of Cancer Therapy; QLQ, quality of life questionnaire
Multiple myeloma is an evolving disease state, and Amgen plans several substantive updates to the content of this site in the coming months. Please subscribe to be notified as these updates become available. Your email will not be used for any other purpose and you can unsubscribe at any time.
Please send me a notification when myelomarevealed.com content is updated.